Report Store | Pharma intelligence
  • My Account
    • 0Shopping Cart
  • $0.00
  • Disease analysis
    • Anemias
    • Bacterial infections
    • Bleeding disorders
    • Brain Cancer
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Cerebrovascular diseases
    • Dermatology
    • Diabetes and diabetic complications
    • Gastroenterology
    • Gastrointestinal cancer
    • Head and Neck Cancer
    • Hypertension
    • Immunology and Inflammation
    • Infectious Diseases
    • Ischemic heart disease
    • Leukemia
    • Lung Cancer
    • Lymphoma
    • Oncology overview
    • Market Spotlight
    • Mens Health
    • Neurology
    • Oncology
    • Ophthalmology
    • Other Hematological Cancers
    • Other metabolic diseases
    • Other Solid Cancers
    • Pain
    • Psychiatry
    • Respiratory
    • Rheumatology
    • Skin cancer
    • Thrombosis
    • Urological cancer
    • Vaccines
    • Viral infections
    • Women’s Health
  • Strategy analysis
    • Bleeding disorders
    • Breast and gynecological cancer
    • Cardiovascular and Metabolic
    • Central Nervous System
    • Commercial Strategy
    • Dealmaking and R&D
    • Head and Neck Cancer
    • Hot Topics
    • Infectious Diseases
    • KOL Insight
    • Leukemia
    • Lung Cancer
    • Manufacturing
    • Market Access
    • Neurology
    • Oncology
    • Outsourcing
    • Pricing & Reimbursement
    • R&D
    • Regulatory & Therapeutic Area
    • Trends
    • Urological cancer
  • Company analysis
    • Big Pharma
    • Emerging Pharma
    • Hot Topics
    • Japan Pharma
    • M&A Analysis
    • Mid Pharma
  • Drug analysis
    • A
    • B-C
    • D-F
    • G-L
    • M-O
    • P-R
    • S-T
    • U-Z
  • MedTech analysis
    • Allergy
    • Autoimmune / Immunology
    • Cardiovascular
    • Dermatology
    • Endocrine
    • ENT / Dental
    • Gastroenterology
    • Hearing
    • Hematology
    • Infectious Diseases
    • Metabolic
    • Neurology
    • Obstetrics / Gynecology
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Osteoporosis
    • Psychiatry
    • Renal
    • Respiratory
    • Rheumatology
    • Urology
  • Opinion & analysis
    • Business Development
    • Business Management
    • Clinical Trials
    • Digital Health
    • Cybersecurity
    • Compliance & Risk
    • Digital patient management
    • Digital policy & regulation
    • Finance & Pricing
    • Healthcare Innovation
    • ICT and Health
    • Leadership
    • Legislation Regulation & Policy
    • Market Access
    • Market Intelligence
    • Medical
    • Pharmaceutical Device
    • Pharmaceutical Research
    • Strategy & Innovation
    • Tech companies & Data
    • Tech & Pharma
  • Blogs
  • Search
  • Menu
You are here: Home > Report library

Report library


  • Sort by Random
    • Default
    • Custom
    • Name
    • Price
    • Date
    • Popularity (sales)
    • Average rating
    • Relevance
    • Random
    • Product ID
  • Display 45 Products per page
    • 15 Products per page
    • 30 Products per page
    • 45 Products per page
  • Ninlaro

    Read More

    Ninlaro (ixazomib; Takeda) reversibly inhibits the 20S proteasome, resulting in the accumulation of proteins and eventually leading to the activation of apoptotic pathways.

    August 9, 2018
    Find out more
  • Market Spotlight: Acne

    $1,318.00

    This Market Spotlight report covers the Acne market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, regulatory events, probability of success, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

    April 7, 2022
    Find out more
  • Gazyva

    Read More

    Gazyva (obinutuzumab; Roche/Biogen/Chugai/Nippon Shinyaku) is a third-generation, type II glycoengineered, humanized anti-CD20 monoclonal antibody (MAb) that recognizes the type II epitope of the CD20 antigen.

    January 31, 2019
    Find out more
  • U.S. Markets for Orthopedic Extremity and Soft Tissue Repair, September 2015

    $5,250.00

    The United States (U.S.) market for orthopedic extremity and soft tissue repair products encompasses interventional surgical procedures and biologic and synthetic implants used in the repair of bone, joints, and soft tissue that have been damaged as a result of disease or due to physical injury.

    September 1, 2015
    Find out more
  • Digital Health Technology and Regulatory Overview

    Digital Health Technology and Regulatory Overview

    $4,750.00

    This technology report provides an overview of the current landscape for digital health devices and software. This includes a summary of regulation and reimbursement policies and highlights of major product categories.

    December 13, 2021
    Find out more
  • ozanimod report

    Ozanimod

    Read More

    Ozanimod (Celgene) is a sphingosine 1-phosphate (S1P) receptor agonist, with selectivity for the sphingosine 1-phosphate type 1 receptor (S1P1) and sphingosine 1-phosphate 5 receptor (S1P5).

    August 2, 2018
    Find out more
  • GSK-3003891A

    Read More

    GSK-3003891A (GlaxoSmithKline) is an alum-adjuvanted respiratory syncytial virus (RSV) vaccine based on the prefusion form of the RSV fusion (F) protein. It is currently in Phase II development in the US and EU.

    October 5, 2018
    Find out more
  • Bococizumab

    Read More

    Bococizumab is an antidyslipidemic humanized antibody that inhibits PCSK9. PCSK9 is a protease involved in the intracellular and extracellular regulation of LDL receptor (LDLR) expression…

    June 29, 2016
    Find out more
  • ganaxolone report

    Ganaxolone

    Read More

    Marinus Pharmaceuticals is developing ganaxolone, a first-in-class synthetic neurosteroid drug for the adjunctive treatment of status epilepticus and pediatric orphan indications.

    May 23, 2017
    Find out more
  • LT-02

    Read More

    LT-02 (Lipid Therapeutics/Dr Falk) is a modified-release formulation of phosphatidylcholine that is in Phase III development for the treatment of ulcerative colitis.

    May 9, 2017
    Find out more
  • Darolutamide

    Read More

    Darolutamide is a non-steroidal oral androgen receptor (AR)antagonist in development by Bayer for the treatment of prostate cancer. Darolutamide potently inhibits the binding of androgens to ARs, blocking nuclear translocation of ARs and AR-mediated gene expression. The AR signaling pathway is the primary pathway that drives prostate cancer growth.

    January 18, 2018
    Find out more
  • Galvus

    Read More

    Galvus (vildagliptin; Novartis) is a member of the dipeptidyl peptidase-IV (DPP-IV) inhibitor class.

    November 7, 2017
    Find out more
  • LR769

    Read More

    LR769 is a recombinant factor VIIa (rfVIIa) therapy in development by LFB for patients with hemophilia A or B with inhibitors.

    May 4, 2018
    Find out more
  • Betaseron

    Read More

    Betaseron was the first drug to reach the market that modifies the course of multiple sclerosis (MS), after launching in the US in 1994 and the EU in 1996 (where it is marketed as Betaferon).

    November 24, 2017
    Find out more
  • Ad26.RSV.preF

    Read More

    Ad26.RSV.preF, in development by Johnson & Johnson, is a replication-deficient vector vaccine that encodes a prefusion form of the RSV F protein.

    October 5, 2018
    Find out more
  • vraylar report

    Vraylar

    Read More

    Vraylar (cariprazine; Gedeon Richter/Allergan/Mitsubishi Tanabe) is a novel atypical antipsychotic with partial agonistic activity at D2 and D3 receptors, and selectivity for the D3 receptor.

    March 29, 2018
    Find out more
  • Market Spotlight: Cachexia

    $1,318.00

    Cachexia is a complex, multifactorial, and multi-organ metabolic syndrome found in the late stages of serious illnesses including cancer, kidney disease, and congestive heart failure.

    July 20, 2022
    Find out more
  • cayson-th

    Cayston

    Read More

    Cayston is an inhalable formulation of the monobactam antibacterial aztreonam and was developed by Gilead.

    September 3, 2018
    Find out more
  • Uptravi

    Read More

    Uptravi (selexipag; Nippon Shinyaku/Actelion) is the first-in-class oral selective non-prostanoid prostaglandin I2 (PGI2) receptor agonist.

    October 29, 2018
    Find out more
  • Imfinzi

    Read More

    Imfinzi (durvalumab; AstraZeneca)  is a human monoclonal antibody directed against programmed death-ligand 1 (PD-L1).

    September 9, 2019
    Find out more
  • Prostate Cancer KOL Interview – US, Northeast #2

    Prostate Cancer KOL Interview – US, Northeast #2

    $599.00

    A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for prostate cancer. Key pipeline assets highlighted include Keytruda, Tecentriq, Opdivo, ipatasertib, capivasertib, Lutetium 177Lu-PSMA-617, and CAN-2409.

    February 9, 2022
    Find out more
  • Abraxane

    Read More

    Abraxane (nab-paclitaxel; Bristol-Myers Squibb) is a novel albumin-bound formulation of paclitaxel. Paclitaxel is an insoluble taxane classified as an anti-microtubule agent; it stops the growth of tumors by inhibiting mitosis during metaphase.

    February 26, 2020
    Find out more
  • Erbitux

    Read More

    Erbitux is a chimeric monoclonal antibody (MAb) that binds to the extracellular domain of epidermal growth factor receptor (EGFR).

    December 11, 2017
    Find out more
  • U.S. Markets for Obesity Drugs & Devices

    $5,250.00

    U.S. Markets for Obesity Drugs & Devices

    September 22, 2016
    Find out more
  • Post-Clinical Trials on Alzheimer’s Disease (CTAD) 2016 Survey

    $599.00

    Biomedtracker conducted a 5-question survey of 51 United States and 47 European (from France, Germany, Italy, Spain and United Kingdom) neurologists who currently treat patients in all stages of Alzheimer’s disease and who followed data presented at Clinical Trials on Alzheimer’s Disease (CTAD) 2016 to gauge their views on the pipeline anti-amyloid beta monoclonal antibodies solanezumab (LLY) and aducanumab (BIIB) and projected use of these potentially disease-modifying drugs if FDA-approved.

    March 9, 2017
    Find out more
  • Disease Analysis: COVID-19 Treatment

    Read More

    COVID-19 is an infectious disease caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus that emerged in late 2019 in Wuhan, China. As of 12 March 2021, there have been 117,799,584 confirmed cases of COVID-19, and 2,615,018 confirmed deaths globally. SARS-CoV-2 belongs to the coronavirus family, which collectively cause respiratory and intestinal disease in humans and animals, with other prominent members of the family including Middle East respiratory syndrome (MERS) virus and severe acute respiratory syndrome (SARS) virus. SARS-CoV-2 is believed to have originated from a horseshoe bat coronavirus, which either spread to humans directly or jumped via an intermediate host (possibly a pangolin), which may have facilitated transmission to humans.

    November 1, 2021
    Find out more
  • R&D Trends 2016

    $2,995.00

    Over the nine-year period from 2006 to 2014, the Big Pharma, Mid Pharma, and Japan Pharma peer sets collectively spent an annual average of $94bn on R&D of pharmaceuticals, with spending growing at a compound annual growth rate (CAGR) of 6%.

    October 17, 2016
    Find out more
  • Orphan Drug Pricing and Reimbursement

    $2,995.00

    Orphan drugs account for a growing portion of payers’ budgets – and comprise some of the most expensive treatments available.

    November 4, 2016
    Find out more
  • The Contract Biomanufacturing Market Outlook to 2017

    $5,000.00

    The biologic drug market is growing at nearly twice the pace of the overall pharmaceutical market, driven by major therapeutic fields under research such as oncology and autoimmune diseases. The forecasted 20% annual increase in biologic active pharmaceutical ingredient (API) demand between 2011 and 2017 combined with the growth of biosimilars will generate a positive environment for the biologics contract manufacturing organization (CMO) market to grow at 9% per year over the same period.

    November 3, 2016
    Find out more
  • General and Pelvic Endoscopic Surgery

    $4,750.00

    This Meddevicetracker report provides an analysis of the market for general and pelvic endoscopic surgery products in the US, five major EU markets, Japan, and the rest of the world. Market segments covered include access devices, access site closure devices, ancillary devices, endoscopes, hand instruments, and insufflation products.

    May 16, 2019
    Find out more
  • MDS/AML KOL Interview

    $599.00

    Highlights More specific, next-generation FLT3 inhibitors may not have an anti-leukemic benefit over agents with broader TKI activity (such as sorafenib, AMGN), but they may not have as severe myelosuppressive effects. Although the kinase inhibitor rigosertib (ONTX) had poor Phase III results in MDS and AML, the subgroup of patients with primary HMA failure may […]

    April 9, 2015
    Find out more
  • Rydapt

    Read More

    Rydapt is a multiple kinase inhibitor that interferes with cellular signal transduction pathways.

    July 6, 2017
    Find out more
  • Specialty Endoscopic Surgery Devices Market

    $4,750.00

    The global market for specialty endoscopic surgery products totaled approximately $5.8bn in 2016, with the US comprising 48.2% of sales (or $2.8bn). Six major product segments are included in the specialty endoscopic surgery products market: endoscopes and equipment; suction/irrigation and fluid management systems, arthroscopic hand instruments, ENT/neurologic hand instruments, thoracoscopic hand instruments, and trocars.

    August 23, 2017
    Find out more
  • Non-Small Cell Lung Cancer KOL Interview

    Non-Small Cell Lung Cancer KOL Interview

    $599.00

    Biomedtracker interviewed a lung cancer specialist based in the US to determine his views on the non-small cell lung cancer treatment landscape, with a focus on PD-1 immunotherapies.

    December 16, 2016
    Find out more
  • Breast Cancer KOL Interview – US, Northeast

    Breast Cancer KOL Interview – US, Northeast

    $599.00

    A US-based key opinion leader (KOL) provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies across all three subtypes of breast cancer. Key pipeline assets highlighted include Enhertu, Trodelvy, Cosela, and enobosarm.

    July 18, 2022
    Find out more
  • Follicular Lymphoma KOL Interview

    $599.00

    “When people need therapy (for advanced stage Follicular Lymphoma), there’s a whole gamut. If they have relatively low volume disease, one option, which unfortunately in the community I would say is underutilized, is single-agent rituximab.”

    February 3, 2016
    Find out more
  • Neurointervention: Mechanical Thrombectomy Devices Market

    $4,750.00

    This medical market and technology report provides a comprehensive discussion of the global market for neurointerventional cerebral aneurysm and arteriovenous malformation (AVM) embolization systems.

    October 30, 2020
    Find out more
  • Disease Analysis: HER2+ Breast Cancer

    Read More

    Amplification of the HER2/neu oncogene and related genetic elements on chromosome 17 increases HER2 expression and accelerates tumorigenesis. The natural disease progression meant that, historically, women with breast cancer who overexpressed HER2 were found to have significantly shorter disease-free survival and overall survival compared with women without HER2 amplification; however, the introduction of trastuzumab in 1998 drastically changed patient outcomes, to the point where HER2+ breast cancer patients now have the longest median survival of all breast cancer subtypes. HER2 is overexpressed in approximately 20% of breast cancers.

    May 20, 2022
    Find out more
  • Xyntha

    Read More

    Xyntha is a recombinant factor VIII (rfVIII) therapy approved for the treatment of hemophilia A.

    Although Pfizer has taken steps to enhance the product by improving the manufacturing processes

    and developing an application device for the therapy, Xyntha’s target patient population will be

    reduced by competitor therapies approved for prophylactic use.

    May 4, 2018
    Find out more
  • Repatha

    Repatha

    Read More

    Repatha (evolocumab; Amgen/Astellas) is a fully human monoclonal immunoglobulin G2 antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9).

    November 20, 2019
    Find out more
  • CMOs in China and India: Still the Places to be?

    $5,000.00

    Low-cost and skilled workforces in China and India have positioned both countries as increasingly important manufacturing hubs for pharmaceutical companies, as they seek to contain costs while retaining quality outsourcing partners.

    Despite the apparent inevitability of the contract manufacturing organization (CMO) sector’s growth in China and India, a recent wave of scandals has put significant dents in the reputations of both countries as locations for foreign firms to manufacture drugs. Rising costs have also caused some firms to question whether using one of the region’s many CMOs is worth the risk.

    November 3, 2016
    Find out more
  • 2015 Post-AAIC KOL Interview

    $599.00

    Following the 2015 Alzheimer’s Association International Conference (AAIC), we interviewed an Alzheimer’s Disease expert on his opinion of the data presentations and the future of Alzheimer’s Disease treatment.

    August 1, 2015
    Find out more
  • Onzeald

    Read More

    Onzeald (etirinotecan pegol; Nektar Therapeutics) is a polyethylene glycol (PEG) conjugate of irinotecan, a prodrug that is metabolized via enzymatic cleavage into the biologically active metabolite 10-hydroxy-7-ethyl camptothecin, also known as SN-38. SN-38 inhibits DNA topoisomerase 1 during the S-phase of the mitotic cycle.

    February 26, 2020
    Find out more
  • pharma_outlook2026

    Big Pharma Outlook 2026

    $2,700.00

    Using in-house sales forecasts, this analysis explores and visualizes market dynamics in the Big Pharma peer set out to 2025.

    June 29, 2017
    Find out more
  • CRO Snapshot 2013

    $5,000.00

    An initial study of the only publicly available data detailing clinical trial starts where contract research organizations (CROs) were named as a collaborator in 2013 shows a 10% lessening in work to the service provider industry.

    November 3, 2016
    Find out more
Page 1 of 29
Page 1 of 29123›»
  • Home
  • Terms and Conditions
  • Refund policy
  • Privacy Policy
  • Cookie Policy
  • Contact Us
  • About Us
  • Discounts
  • Market Spotlight – Reports
  • twitter
  • linkedin
  • Sitemap
Copyright © 2022 Pharma Intelligence UK Limited Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. Pharma Intelligence UK Limited is part of the Pharma Intelligence Group.

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
Call Back
Scroll to top